Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. reported preliminary financial results for the year ended December 31, 2024, highlighting a strong cash position and upcoming FDA decision on TNX-102 SL for fibromyalgia management. Financial Summary - The company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024, which is expected to fund operations into the first quarter of 2026 [5][2] - Net cash used in operating activities was approximately$60.9 million, a decrease from $102.0 million in the prior year [5] - Capital expenditures were approximately$0.1 million, significantly lower than $29.1 million for the prior year [5] - The net operating loss was approximately$126.6 million, including non-cash impairment charges of approximately $59.0 million, compared to a net operating loss of$116.7 million in the prior year [5] - Net revenue from marketed products was approximately $10.1 million, an increase from$7.8 million in the prior year [5] Debt Status - The company is now debt-free after repaying a mortgage with JGB Capital and related parties [5] Product Development - TNX-102 SL, a product candidate for fibromyalgia, has a PDUFA goal date of August 15, 2025, for FDA marketing authorization [3][6] - The FDA has granted Fast Track designation to TNX-102 SL for fibromyalgia management [6] - The company is also developing TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection and autoimmune diseases [6] Market Position - Tonix Pharmaceuticals is focused on transforming therapies for pain management and vaccines for public health challenges, with a development portfolio centered on CNS disorders [6]